Demographic and laboratory characteristics of study subjects
| Characteristic . | SCD (n = 74) . | Control (n = 19) . | P . |
|---|---|---|---|
| Median age, y (IQR) | 41 (30-48.3) | 33 (22-50) | NS |
| Female sex, n (%) | 47 (64) | 15 (79) | NS |
| Genotype, n | — | ||
| SS | 62 | — | |
| SC | 8 | — | |
| Sβ0 | 3 | — | |
| Sβ+ | 1 | — | |
| PASP, mm Hg, median (IQR) | 31 (23-39) | 26 (23-28) | < .001 |
| TRjet, m/s, median (IQR) | 2.3 (1.8-2.7) | 2.0 (1.8-2.1) | .009 |
| White blood cell count, ×109/L, median (IQR) | 9.4 (7.4-11.5) | 7.2 (6.1-9.7) | .001 |
| Hemoglobin level, g/dL, median (IQR) | 8.9 (7.6-10.2) | 12.4 (11.9-13.5) | < .001 |
| Platelet count, ×109/L, median (IQR) | 426 (325.5-512) | 284 (265-322) | < .001 |
| Reticulocyte count, %, median (IQR percentile) | 6.9 (4.5-10.5) | 1.5 (1.3-1.9) | < .001 |
| Absolute neutrophil count, ×109/L, median (IQR) | 5.1 (4-6.2) | 4.7 (4-6.5) | NS |
| Absolute monocyte count, ×109/L, median (IQR) | 0.5 (0.3-0.7) | 0.4 (0.3-0.4) | < .001 |
| Hydroxyurea use, n (%) | 39 (53) | — | — |
| NT-proBNP level, pg/dL, median (IQR) | 133.5 (60.3-326) | 49 (49-59) | < .001 |
| Creatinine level, mg/dL, median (IQR) | 0.75 (0.6-1) | 0.8 (0.7-0.9) | NS |
| Total bilirubin level, mg/dL, median (IQR) | 2.2 (1.2-2.9) | 0.3 (0.2-0.4) | < .001 |
| Direct bilirubin level, mg/dL, median (IQR) | 0.09 (0.09-0.1) | 0.09 (0.09-0.09) | NS |
| LDH level, U/L, median (IQR) | 898 (658-1199) | 488 (413-516) | < .001 |
| PlGF level, pg/mL, median (IQR) | 9.03 (6-11.4) | 0.23 (0-6.8) | < .001 |
| Characteristic . | SCD (n = 74) . | Control (n = 19) . | P . |
|---|---|---|---|
| Median age, y (IQR) | 41 (30-48.3) | 33 (22-50) | NS |
| Female sex, n (%) | 47 (64) | 15 (79) | NS |
| Genotype, n | — | ||
| SS | 62 | — | |
| SC | 8 | — | |
| Sβ0 | 3 | — | |
| Sβ+ | 1 | — | |
| PASP, mm Hg, median (IQR) | 31 (23-39) | 26 (23-28) | < .001 |
| TRjet, m/s, median (IQR) | 2.3 (1.8-2.7) | 2.0 (1.8-2.1) | .009 |
| White blood cell count, ×109/L, median (IQR) | 9.4 (7.4-11.5) | 7.2 (6.1-9.7) | .001 |
| Hemoglobin level, g/dL, median (IQR) | 8.9 (7.6-10.2) | 12.4 (11.9-13.5) | < .001 |
| Platelet count, ×109/L, median (IQR) | 426 (325.5-512) | 284 (265-322) | < .001 |
| Reticulocyte count, %, median (IQR percentile) | 6.9 (4.5-10.5) | 1.5 (1.3-1.9) | < .001 |
| Absolute neutrophil count, ×109/L, median (IQR) | 5.1 (4-6.2) | 4.7 (4-6.5) | NS |
| Absolute monocyte count, ×109/L, median (IQR) | 0.5 (0.3-0.7) | 0.4 (0.3-0.4) | < .001 |
| Hydroxyurea use, n (%) | 39 (53) | — | — |
| NT-proBNP level, pg/dL, median (IQR) | 133.5 (60.3-326) | 49 (49-59) | < .001 |
| Creatinine level, mg/dL, median (IQR) | 0.75 (0.6-1) | 0.8 (0.7-0.9) | NS |
| Total bilirubin level, mg/dL, median (IQR) | 2.2 (1.2-2.9) | 0.3 (0.2-0.4) | < .001 |
| Direct bilirubin level, mg/dL, median (IQR) | 0.09 (0.09-0.1) | 0.09 (0.09-0.09) | NS |
| LDH level, U/L, median (IQR) | 898 (658-1199) | 488 (413-516) | < .001 |
| PlGF level, pg/mL, median (IQR) | 9.03 (6-11.4) | 0.23 (0-6.8) | < .001 |
SCD indicates sickle cell disease; IQR, interquartile range; NS, not significant; PASP, pulmonary arterial systolic pressure; TRjet, tricuspid regurgitant jet velocity; NT-proBNP, N terminal pro-brain natriuretic peptide; LDH, lactate dehydrogenase; and PlGF, placenta growth factor.